Edwards Lifesciences Corp

EW: XNYS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
gp!LOCK|T%$?LOCK|PH$jld<

Edwards Lifesciences Earnings: Strong Start to 2026 Spurs Boost in Management Outlook

Edwards delivered first-quarter results including constant-currency top-line and adjusted bottom-line growth of 13% and 20%, respectively. Quarterly transcatheter aortic valve replacement sales were up 11%, and transcatheter mitral and tricuspid revenue increased over 40% off a smaller base.

Sponsor Center